



Oral Immunotherapy and Viaskin® Peanut for Peanut Allergy: Effectiveness and Value

Tuesday • June 11, 2019 • 10:00 am to 4:00 pm

Laurel Room, California Endowment Oakland Conference Center, 2000 Franklin Street, Oakland, CA 94612

Time	Activity
9:30 am—10:00 am	Registration for Public Attendees
10:00 am—10:15 am	Meeting Convened and Opening Remarks Steve Pearson, MD, MSc, President, ICER
10:15 am—10:45 am	Presentation of the Clinical Evidence Jeffrey A. Tice, MD, University of California, San Francisco
10:45 am – 10:55 am	Presentation of the Caregiver Survey Kenneth Mendez, MBA, Asthma and Allergy Foundation of America
10:55 am – 11:25 am	Presentation of the Economic Model Greg Guzauskas, MSPH, PhD, University of Washington
11:25 am—11:45 am	Manufacturer Comments and Discussion
11:45 am—12:00 pm	Public Comments and Discussion
12:00 pm—1:00 pm	Lunch
1:00 pm—2:00 pm	CTAF Vote on Clinical Effectiveness and Value
2:00 pm—2:15 pm	Break
2:15 pm—3:30 pm	Policy Roundtable
3:30 pm—4:00 pm	Reflections from CTAF
4:00 pm	Meeting Adjourned

ICER Staff and Consultants*	
Pamela Bradt, MD, MPH , Chief Scientific Officer, ICER	Steve Pearson, MD, MSc , President, ICER
Laura Cianciolo, BA , Program Associate, ICER	David Rind, MD, MSc , Chief Medical Officer, ICER
Sarah K. Emond, MPP , Executive Vice President and Chief Operating Officer, ICER	Celia Segel, MPP , Director of Comparative Effectiveness Research Policy Development, ICER
Greg Guzauskas, MSPH, PhD , Research Scientist, University of Washington School of Pharmacy	Matt Seidner, BS , Program Director, ICER
Ryan Hansen, PhD, PharmD , Assistant Professor, University of Washington School of Pharmacy	Jeffrey A. Tice, MD , Professor of Medicine, University of California, San Francisco
Serina Herron-Smith, BA , Research Assistant, ICER	Tia Tilson, BA , Vice President of Development, ICER

*No conflicts of interest to disclose, defined as individual health care stock ownership in any health plan or pharmaceutical, biotechnology, or medical device manufacturers, or any health care consultant income or honoraria from health plans or manufacturers.

Participating Members of CTAF	
Ralph G. Brindis, MD, MPH, MACC, FSCAI, FAHA,* Clinical Professor of Medicine, University of California, San Francisco	Sei Lee, MD,* Associate Professor of Medicine, University of California San Francisco
Felicia Cohn, PhD,* Bioethics Director, Kaiser Permanente, Orange County	Joy Melnikow, MD, MPH,* Director, Center for Healthcare Policy and Research, University of California, Davis
Robert Collyar,* Patient Advocate	Elizabeth J. Murphy, MD, DPhil,* Professor of Clinical Medicine, University of California San Francisco; Chief, Division of Endocrinology and Metabolism, Zuckerberg San Francisco General Hospital
Rena K. Fox, MD,* Professor of Medicine, University of California, San Francisco	Rita F. Redberg, MD, MSc, FACC,* Professor, University of California, San Francisco School of Medicine
Kimberly Gregory, MD, MPH,* Vice Chair, Women's Healthcare Quality and Performance Improvement, Cedars-Sinai Medical Center	William Remak, BSc, MT, BPH,* Chairman/CEO, California Hepatitis C Task Force, Inc
Paul Heidenreich, MD, MS (Chair),* Professor and Vice-Chair for Quality, Clinical Affairs, and Analytics, Stanford University	Robert Rentschler, MD,* Retired, Beaver Medical Group
Jeffrey Hoch, PhD,* Associate Director, Center for Healthcare Policy and Research, University of California, Davis	Richard Seiden, JD,* Patient Advocate, Retired Partner, Foley & Lardner LLP
Jeffrey Klingman, MD,* Chief of Neurology, The Permanente Medical Group	Alexander Smith, MD, MPH,* Associate Professor of Medicine, University of California, San Francisco
Neal Kohatsu, MD, MPH, FACPM,* Population Health Consultant, Kohatsu Consulting	

* No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

Policy Roundtable Participant	Conflict of Interest
Todd Green, MD, FAAAA, Vice President Medical Affairs North America, DBV Technologies	Employee of DBV Technologies.
Matthew Greenhawt, MD, Associate Professor of Pediatrics, University of Colorado School of Medicine, Section of Allergy/Immunology, Children's Hospital Colorado; Director, Food Challenge and Research Unit	Dr. Greenhawt has served as a paid consultant for Aimmune Therapeutics and has received honorarium while serving as a member of physician/medical advisory boards for Aimmune Therapeutics and DBV Technologies.
Ruchi Gupta, MD, MPH, Professor of Pediatrics and Medicine, Northwestern University Feinberg School of Medicine; Clinical Attending, Ann & Robert H. Lurie Children's Hospital of Chicago; Director, Center for Food Allergy & Asthma Research; Director, Science & Outcomes of Allergy & Asthma Research Program	Dr. Gupta has received grants from Aimmune Therapeutics and has served as a medical consultant for DBV Technologies and Aimmune Therapeutics.
Nurry Hong, Chief of Strategy and Innovation, Food Allergy Research & Education	FARE, a 501(c)(3), has received general support grants or corporate sponsorship from DBV Technologies and Aimmune Therapeutics. FARE was a shareholder of Aimmune, but those shares were sold in 2016.
Caroline Moassessi, Patient Advocate	None disclosed.
Stephen Tilles, MD, Senior Director of Medical Affairs, Aimmune Therapeutics	Employee of Aimmune Therapeutics.
John S. Yao, MD, MPH, MBA, MPP, CPC, FACP, Regional Vice President and Chief Medical Officer, Anthem Blue Cross	Employee of Anthem Blue Cross.